Portfolio Overview


The Mark Foundation provides grant support to an expanding network of scientists conducting research across cancer types. From individual investigators to multidisciplinary collaborative teams, our awardees represent the best scientific minds in cancer research and technological innovation and become a vital part of our scientific network.

The Mark Foundation employs various funding mechanisms, both independent and in collaboration with partner organizations. All grant submissions undergo rigorous peer review and are held to the strictest standards of scientific excellence.

100 Grants

Over $90 Million Awarded


  • 43% Translational Science
  • 26% Technology Innovation
  • 23% Basic Research
  • 3% Clinical
  • 5% Therapeutic Discovery

Funding By Cancer Type


  • 47% All cancer types
  • 8% Brain Tumors
  • 9% Leukemia
  • 7% Melanoma
  • 9% Others
  • 4% Pancreatic Cancer
  • 6% Breast Cancer
  • 3% Lung Cancer
  • 3% Colorectal Cancer
  • 2% Lymphoma
  • 1% Ovarian Cancer
  • 1% Prostate Cancer

Over 50 Institutions

In 6 Countries


  • CANADA
  • NETHERLANDS
  • Denmark
  • UNITED KINGDOM
  • FRANCE
  • USA

Project Awards


Project-based awards, led by individual investigators or teams, enable innovation that provides solutions to high-impact problems in cancer research that tend to fall outside the scope of other funding opportunities. We fund projects through grant vehicles including our ASPIRE Award (Accelerating Scientific Platforms and Innovative Research) and our new Drug Discovery Program that will bridge the gap between academic discoveries and the clinic for new cancer therapeutics.


Investigator Awards


Our vision is to continually enable research that will lead to transformative benefits for patients with impact that grows exponentially over time. Awards to investigators at different career stages, with a special focus on early-career scientists, help us achieve this vision. Investigator-focused programs include our Emerging Leader Award and Fellowship programs

Multidisciplinary Teams


We are committed to funding interdisciplinary research that promises to transform how cancer is prevented, diagnosed, and treated.


Investments


The Mark Foundation is an investor in Accent Therapeutics, GRAIL, and Verseau Therapeutics.

LEARN MORE